Gore’s Cardioform ASD Occluder Approved and Launched in Europe


October 2, 2019—Gore & Associates announced CE Mark approval and the European launch of the Cardioform atrial septal defect (ASD) occluder for percutaneous transcatheter closure of ostium secundum ASDs.

According to Gore, the Cardioform ASD occluder’s anatomically adaptable waist conforms to the defect to close ASDs with diameters of 8 to 35 mm, including those without a retroaortic rim, by facilitating optimal tissue ingrowth while maintaining thromboresistance. The ability to retrieve and reposition the device helps ensure proper positioning and offers physicians confident closure.

The recent ASSURED clinical study evaluated the safety and efficacy of ASD closure using the Cardioform device in 125 patients with evidence of right heart volume overload demonstrating the need for defect closure. The study included patients between the ages of 2 and 84, across 22 investigation sites, including 15 children’s hospitals. The pivotal study met its safety, closure, and technical success primary endpoints.

In June 2019, Gore announced that the Cardioform ASD occluder received premarket approval from the FDA for treatment of ASDs in the United States.

Matthew Gillespie, MD, Coprincipal Investigator of the ASSURED clinical study, commented in Gore’s announcement, “Larger defects typically have a greater risk for complications, like pulmonary hypertension, right heart enlargement, or atrial fibrillation. But previously, Europe didn’t have access to the Gore Cardioform ASD occluder for this range of defects. CE Mark makes this soft, conformable device available for the minimally invasive treatment of a broader range of ASDs.” Dr. Gillespie is from Children’s Hospital of Philadelphia in Philadelphia, Pennsylvania.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.